Publications (162) ESTHER GONZÁLEZ MONTE publications

2024

  1. A personalised delisting strategy enables successful kidney transplantation in highly sensitised patients with preformed donor-specific anti HLA antibodies

    HLA, Vol. 103, Núm. 6

  2. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting

    HemaSphere, Vol. 8, Núm. 7

  3. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell–Depleting Agents

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1812-1816

  4. Human microRNA sequencing and cytomegalovirus infection risk after kidney transplantation

    American Journal of Transplantation, Vol. 24, Núm. 7, pp. 1180-1192

  5. Prophylactic Anticoagulation Reduces the Risk of Kidney Graft Venous Thrombosis in Recipients from Uncontrolled Donation after Circulatory Death Donors with High Renal Resistive Index

    Transplantation Direct, Vol. 10, Núm. 6, pp. E1649

  6. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  7. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice

    Clinical Kidney Journal, Vol. 17, Núm. 4

2023

  1. A joint program of antimicrobial stewardship and hospital-acquired infection control to reduce healthcare-associated infections after kidney transplantation: The Hipomenes study

    American Journal of Transplantation, Vol. 23, Núm. 12, pp. 1949-1960

  2. Best practices during COVID-19 pandemic in solid organ transplant programs in Spain

    Transplantation Reviews, Vol. 37, Núm. 1

  3. Erratum to “Recommendations for living donor kidney transplantation” (NEFROLOGÍA (2022) 42(S2) (129–132), (S0211699522000133), (10.1016/j.nefro.2022.01.007))

    Nefrologia

  4. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

  5. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 10, pp. e341-e347

  6. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

    Clinical Kidney Journal, Vol. 16, Núm. 10, pp. 1656-1663

2022

  1. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study

    Clinical transplantation, Vol. 36, Núm. 3, pp. e14550

  2. Fluconazole versus micafungin for initial antifungal prophylaxis against Candida in pancreas transplant recipients: A comparative study of two consecutive periods

    Mycoses, Vol. 65, Núm. 5, pp. 517-525

  3. Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation

    Scientific Reports, Vol. 12, Núm. 1

  4. Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates

    Transplant Infectious Disease, Vol. 24, Núm. 1

  5. Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation

    Frontiers in Genetics, Vol. 13

  6. Influence of single-nucleotide polymorphisms in TLR3 (rs3775291) and TLR9 (rs352139) on the risk of CMV infection in kidney transplant recipients

    Frontiers in Immunology, Vol. 13

  7. Recommendations for living donor kidney transplantation

    Nefrologia, Vol. 42, pp. 5-132